Downstream AAV Production: Tools For Efficient And Reliable Gene Therapy Manufacturing

By Paul Cashen, Katy McLaughlin, and Benjamin Graf, Sartorius

Efficient downstream processing of adeno-associated virus (AAV) vectors is critical to advancing gene therapy from research to clinical and commercial manufacturing. This white paper explores the unique challenges of AAV purification—including low yields, impurity removal, and serotype-specific process variability—and offers practical strategies to overcome them. Explore a scalable framework for downstream workflows, emphasizing early-stage decisions that impact long-term success. Key technologies are highlighted, such as monolithic chromatography for capsid separation, high-throughput filtration systems, and automated analytical tools that accelerate development and improve product characterization. For teams navigating the complexities of AAV manufacturing, gain actionable insights to streamline development and reduce risk.

Access the full white paper to learn how to build a reliable, scalable AAV purification process that meets clinical and regulatory demands.